Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists

References

• Schröder F, Crawford ED, Axcrona K, et al. Androgen deprivation therapy: past, present and future. BJU International. 2012;109(s6):1–12.
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verhagen PC, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer. 2008;44(9):1193–1197.
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol. 2008;19(Suppl 7):vii91–vii95.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, Castration-Resistant prostate cancer. N Engl J Med. 2020;382(23):2197–2206.
   PubMed Web of Science ®Google Scholar
• Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162). J Clin Oncol. 2006;24(24):3984–3990.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040–1049.
   PubMed Web of Science ®Google Scholar
• Enblad AP, Bergengren O, Andrén O, et al. PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing. Scand J Urol. 2020;54(5):376–376.
   PubMed Web of Science ®Google Scholar
• Aly M, Leval A, Schain F, et al. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scand J Urol. 2020;54(2):115–121.
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. Population 1 November by region, age and sex. Year 2002–2019; 2018. Available from: https://www.statistikdatabasen.scb.se/pxweb/sv/ssd/START__BE__BE0101__BE0101A/FolkmangdNov/.
   Google Scholar
• Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base-a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82.
   PubMed Web of Science ®Google Scholar
• Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the Swedish prescribed drug register – a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464–469.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Svedberg P, Olén O, et al. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423–437.
   PubMed Web of Science ®Google Scholar
• Fall K, Strömberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352–357.
   PubMed Web of Science ®Google Scholar
• Mixed GAM computation vehicle with automatic smoothness estimation. Available from: https://CRAN.R-project.org/package=mgcv.
   Google Scholar
• Hosmer DL. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
   Google Scholar
• Eisenberger M, Crawford E, McLeod D, et al. The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105. J Clin Oncol. 1995;14:235a.
   Google Scholar
• Keto CJ, Aronson WJ, Terris MK, et al. Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol. 2014;65(3):620–627.
   PubMed Web of Science ®Google Scholar
• Benaim EA, Pace CM, Lam PM, et al. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology. 2002;59(1):73–78.
   PubMed Web of Science ®Google Scholar
• Stewart AJ, Scher HI, Chen MH, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005;23(27):6556–6560.
   PubMed Web of Science ®Google Scholar
• Pettersson B, Varenhorst E, Petas A, et al. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Eur Urol. 2006;50(3):483–489.
   PubMed Web of Science ®Google Scholar
• Samverkan RCi. Nationellt vårdprogram prostatacancer 2021. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/prostatacancer/vardprogram/.
   Google Scholar
• Lissbrant IF, Garmo H, Widmark A, et al. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593–1601.
   PubMed Web of Science ®Google Scholar
• Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–111.
   PubMed Web of Science ®Google Scholar